Biopharmaceutical firm Tolero Pharmaceuticals and AbbVie have formed a clinical research alliance to evaluate venetoclax and alvocidib combination for relapsed or refractory acute myeloid leukaemia (AML) treatment.
Astellas has filed its experimental Acute Myeloid Leukaemia (AML) therapy gilteritinib with US regulators, seeking approval for its use to treat FLT3 mutation-positive (FLT3mut+) relapsed or refractory forms of the blood cancer.